Skip to main content
K

KPC PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · 600422 LEI · 3003007ZALHXKUFMKN96 Shanghai Stock Exchange Manufacturing
Filings indexed 2,726 across all filing types
Latest filing 2026-03-19 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600422

About KPC PHARMACEUTICALS, INC.

KPC Pharmaceuticals, Inc. specializes in the research, development, and manufacturing of pharmaceutical products, with a significant focus on natural and botanical medicines. The company is a global leader in the production of artemisinin-based anti-malarial treatments, including artemether and its derivatives. Its portfolio encompasses a wide range of therapeutic areas, notably cardiovascular and cerebrovascular health, where it utilizes Panax notoginseng saponins as a core component. KPC integrates traditional medicinal knowledge with modern pharmacological techniques to develop standardized botanical extracts and chemical drugs. The organization operates extensive production facilities and research centers dedicated to drug discovery and quality control. Its business activities extend to the distribution of healthcare products and the provision of medical services, aiming to provide comprehensive health solutions through innovation in natural medicine and biotechnology.

Recent filings

Filing Released Lang Actions
昆药集团2025年度独立董事述职报告(王桂华)
Regulatory Filings
2026-03-19 Chinese
昆药集团2025年度审计报告
Regulatory Filings
2026-03-19 Chinese
昆药集团对2025年度会计师事务所履职情况的评估报告
Regulatory Filings
2026-03-19 Chinese
昆药集团董事会审计与风险控制委员会对会计师事务所2025年度履行监督职责情况的报告
Regulatory Filings
2026-03-19 Chinese
昆药集团2025年度审计与风险控制委员会履职报告
Regulatory Filings
2026-03-19 Chinese
昆药集团2025年度业绩快报
Regulatory Filings
2026-02-06 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.